help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2003-0636
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
145/2/620    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fowlkes, J. L.
Right arrow Articles by Nagase, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fowlkes, J. L.
Right arrow Articles by Nagase, H.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*L-TYROSINE
Endocrinology Vol. 145, No. 2 620-626
Copyright © 2004 by The Endocrine Society

Regulation of Insulin-Like Growth Factor (IGF)-I Action by Matrix Metalloproteinase-3 Involves Selective Disruption of IGF-I/IGF-Binding Protein-3 Complexes

John L. Fowlkes, Delila M. Serra, R. Clay Bunn, Kathryn M. Thrailkill, Jan J. Enghild and Hideaki Nagase

Department of Pediatrics (J.L.F., R.C.B., K.M.T.), University of Arkansas for Medical Sciences and Arkansas Children’s Hospital Research Institute, Little Rock, Arkansas 72202; Department of Pediatrics (D.M.S.), Duke University Medical Center, Durham, North Carolina 27710; Department of Molecular and Structural Biology (J.J.E.), University of Aarhus, DK-8000 Aarhus C, Denmark; and Kennedy Institute of Rheumatology Division (H.N.), Faculty of Medicine, Imperial College London, London W6 8LH, United Kingdom

Address all correspondence and requests for reprints to: John L. Fowlkes, M.D., Professor and Chief, Division of Pediatric Endocrinology and Diabetes, University of Arkansas for Medical Sciences, Arkansas Children’s Hospital, Arkansas Children’s Hospital Research Institute, 800 Marshall Street, Slot 512-6, Little Rock, Arkansas 72202. E-mail: fowlkesjohnl{at}uams.

IGF-I and IGF-II play important roles in growth and development via interactions with cell-surface receptors; however, in nature, IGFs are sequestered by at least six soluble, high-affinity IGF-binding proteins (IGFBPs), namely IGFBPs 1–6. Herein, we demonstrate that the stromal cell-derived extracellular matrix-degrading metalloproteinase stromelysin 1 (matrix metalloproteinase 3) disrupts IGF/IGFBP-3 complexes and liberates free, intact IGFs, leading to phosphorylation of cell surface type 1 IGF receptors and cellular proliferation. Tissue inhibitor of metalloproteinases (TIMP-1) or an antibody to the type 1 IGF receptor mitigates IGF-mediated cellular proliferation. Thus, these studies suggest that matrix metalloproteinases, beyond their effects on extracellular matrix turnover, regulate cellular proliferation by modulating the bioavailability of IGFs, an event critical for such diverse phenomena as embryo development, morphogenesis, angiogenesis, and tumorigenesis.




This article has been cited by other articles:


Home page
J. Neurosci.Home page
P. H. Larsen, A. G. DaSilva, K. Conant, and V. W. Yong
Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice.
J. Neurosci., February 22, 2006; 26(8): 2207 - 2214.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
M. Ii, H. Yamamoto, Y. Adachi, Y. Maruyama, and Y. Shinomura
Role of Matrix Metalloproteinase-7 (Matrilysin) in Human Cancer Invasion, Apoptosis, Growth, and Angiogenesis
Experimental Biology and Medicine, January 1, 2006; 231(1): 20 - 27.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
R. H. Stephens, P. McElduff, A. H. Heald, J. P. New, J. Worthington, W. E. Ollier, and J. M. Gibson
Polymorphisms in IGF-Binding Protein 1 Are Associated With Impaired Renal Function in Type 2 Diabetes
Diabetes, December 1, 2005; 54(12): 3547 - 3553.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
T. Ogawa, T. Nikawa, H. Furochi, M. Kosyoji, K. Hirasaka, N. Suzue, K. Sairyo, S. Nakano, T. Yamaoka, M. Itakura, et al.
Osteoactivin upregulates expression of MMP-3 and MMP-9 in fibroblasts infiltrated into denervated skeletal muscle in mice
Am J Physiol Cell Physiol, September 1, 2005; 289(3): C697 - C707.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. Hemers, C. Duval, C. McCaig, M. Handley, G. J. Dockray, and A. Varro
Insulin-Like Growth Factor Binding Protein-5 Is a Target of Matrix Metalloproteinase-7: Implications for Epithelial-Mesenchymal Signaling
Cancer Res., August 15, 2005; 65(16): 7363 - 7369.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
S. A. Gharib, D. L. Luchtel, D. K. Madtes, and R. W. Glenny
Global gene annotation analysis and transcriptional profiling identify key biological modules in hypoxic pulmonary hypertension
Physiol Genomics, June 16, 2005; 22(1): 14 - 23.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society